US Markets

Indivior to pay $600 million to resolve U.S. opioid treatment marketing claims

Indivior Plc on Friday said it had agreed to pay $600 million and have a subsidiary plead guilty to a criminal charge to resolve U.S. allegations that it engaged in an illegal scheme to boost prescriptions of its opioid addiction treatment Suboxone.

July 24 (Reuters) - Indivior Plc on Friday said it had agreed to pay $600 million and have a subsidiary plead guilty to a criminal charge to resolve U.S. allegations that it engaged in an illegal scheme to boost prescriptions of its opioid addiction treatment Suboxone.

The company said it had reached the agreement with the U.S. Justice Department, the Federal Trade Commission and U.S. state attorneys general and will make the payments over a period of seven years. (Reporting by Nate Raymond in Boston; editing by Jonathan Oatis) ((Nate.Raymond@thomsonreuters.com and Twitter @nateraymond; 617-856-1312; Reuters Messaging: nate.raymond.thomsonreuters.com@reuters.net)) Keywords: USA INDIVIOR/SETTLEMENT (URGENT)

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Latest Markets Videos

Reuters

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

Learn More